Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Radiochemotherapy Clear all
Completed No phase listed Observational

A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC

NCT00483821
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
medical chart review
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 25, 2026, 9:20 AM EDT
Terminated Phase 1 Interventional

Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC

NCT02987998
View directory record Official record
Conditions
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Pembrolizumab, Radiation
Drug
Lead sponsor
Nathan Pennell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

NCT02655601
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
Interventions
BMX-001, Radiation Therapy, Temozolomide
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 25, 2026, 9:20 AM EDT
Terminated Not applicable Interventional Results available

Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy

NCT02145390
View directory record Official record
Conditions
Bladder Cancer, Bladder Carcinoma, Transition Cell Cancer, Muscle Invasive Bladder Carcinoma
Interventions
Transurethral Resection of the Bladder Tumor & Cystoscopy, Intensity Modulated Radiation Therapy, Expanded Prostate Cancer Index Composite Short Form 12, International Prostate Symptom Score
Procedure · Radiation · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 25, 2026, 9:20 AM EDT
Terminated Phase 3 Interventional Results available

Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

NCT00303628
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions
oxaliplatin, fluorouracil, leucovorin calcium, bevacizumab
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
600
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 386 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Not applicable Interventional Results available

Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom

NCT05140902
View directory record Official record
Conditions
Glioblastoma
Interventions
Point-of-care Portable Perfusion Phantom (P4)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT01076231
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer
Interventions
proton beam radiation therapy, cisplatin, etoposide, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 25, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00551759
View directory record Official record
Conditions
Esophageal Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Cetuximab, Docetaxel, Surgery, Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
109
States / cities
Lewes, Delaware • Newark, Delaware • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trimodality Management of T1b Esophageal Cancers

NCT01217060
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Docetaxel, 5-FU, Radiotherapy, Esophagectomy, Dexamethasone
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 25, 2026, 9:20 AM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

NCT05366179
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CAR.B7-H3T cells infusion
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

NCT00638612
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
AdV-tk, Valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Duarte, California • La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

NCT04474353
View directory record Official record
Conditions
Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
Optune, Gadolinium, Temozolomide, Stereotactic radiosurgery (SRS)
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 25, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Results available

Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)

NCT00664105
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Docetaxel, radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Orlando, Florida • Baltimore, Maryland • Cleveland, Ohio + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 25, 2026, 9:20 AM EDT
Not listed Phase 2 Interventional

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

NCT02037048
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer
Interventions
oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, radiation therapy, carboplatin, paclitaxel
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 25, 2026, 9:20 AM EDT
Recruiting Phase 2 Interventional

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

NCT04682158
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
Carboplatin, 3 Dimensional Conformal Radiation Therapy, Propranolol, Intensity Modulated Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 25, 2026, 9:20 AM EDT
Active, not recruiting Phase 1 Interventional

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT03587038
View directory record Official record
Conditions
Glioblastoma
Interventions
OKN 007, Temozolomide, Photon/Proton IMRT
Drug · Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Early Phase 1 Interventional

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

NCT05816785
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
Cetuximab, Imatinib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Results available

Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer

NCT00250835
View directory record Official record
Conditions
Rectal Cancer
Interventions
Chemotherapy, Celecoxib, and Radiation
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

NCT02324335
View directory record Official record
Conditions
Head and Neck Neoplasms, Mucositis
Interventions
Brilacidin, Placebo
Drug · Other
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer

NCT02283372
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
nab-Paclitaxel, Gemcitabine, Intensity modulated radiation
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 25, 2026, 9:20 AM EDT
Active, not recruiting No phase listed Observational

Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks

NCT04975139
View directory record Official record
Conditions
Glioma
Interventions
RS-fMRI
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 25, 2026, 9:20 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

NCT07281417
View directory record Official record
Conditions
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Cemiplimab, Chemoradiotherapy, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Surgical Procedure
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

NCT02805179
View directory record Official record
Conditions
Glioma
Interventions
High Dose Radiation, Temozolomide
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 25, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

BION Treatment of Dysphagia After Radical Head-Neck Surgery

NCT00628485
View directory record Official record
Conditions
Dysphagia
Interventions
BION
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 25, 2026, 9:20 AM EDT